William Blair initiated coverage on Concentra Group Holdings with an Outperform rating, citing strong results and a premium valuation. The firm highlights CON's leadership in occupational medicine, a solid Q1 beat (EPS 0.40; revenue $569.56M) and raised FY2026 sales guidance to $2.27–$2.375B, suggesting a potential re-rating of the stock.
Select Medical will distribute 81.7% of Concentra's shares to shareholders. Concentra's target price is set at $21.00 per share post-spin-off. The distribution is tax-free for US federal income tax purposes. Concentra must navigate potential economic headwinds affecting revenue. Select Medical aims to maximize shareholder value through this separation.
Concentra's IPO included 22.5 million shares priced at $23.50 each. RBC Capital initiated coverage, highlighting Concentra's growth potential. The firm predicts Concentra's valuation will improve post-IPO. Analysts see minimal regulatory challenges impacting revenue. Concentra services over 50,000 patients daily across 41 states.
Deutsche Bank initiated coverage on CON with a Buy rating. Price target set at $29, indicating strong upside potential. CON's growth potential driven by market strength and management execution. Recent fee schedule increase in Florida likely boosts 2025 revenue by 1.4%-1.8%. CON shows strong free cash flow for rapid de-leveraging and reinvestment.
Continental may spin off a loss-making automotive-electronics unit. The automotive-electronics unit employs around 100,000 people. A spin-off could provide competitive opportunities and investment flexibility. The board will decide by Q4, aiming for shareholder vote next year. Continental's remaining business will focus on tires and industrial solutions.
Continental AG expects growth in China to boost profits in Q2 2024. Chinese car market rebound to positively impact tires and auto parts segments. Wall Street adjusts estimates downward for electric-vehicle maker's Q2 delivery report.